Pain scale

Neodymium-Iron-Boron Magnet Global Market Report 2022: Increasing Employment in Robotics to Power Wheels, Sensors, and Motion Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Natural Resources, Other Natural Resources, Mining, Minerals, Magnet, Astronaut, Computer, Arthritis, Efficiency, Microwave, Wound healing, Employment, CAGR, Neodymium, Neodymium magnet, Headache, Motion, Wind, Iron, Boron, Robotics, Insomnia, Pain scale, ACS, Magnetic resonance imaging, Rare-earth element, Electric motor, Growth

The "Neodymium-Iron-Boron Magnet Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neodymium-Iron-Boron Magnet Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global neodymium-iron-boron magnet market size reached US$ 13.6 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 21.1 Billion by 2027, exhibiting a CAGR of 7.59% during 2021-2027.
  • Besides this, the increasing employment of NdFeB magnets in robotics to power wheels, sensors, and motion is contributing to the growth of the market.

Benefit Packages 2023 Address Back Pain in the Workplace, Foot Levelers Cites Importance of Non-Invasive Care: Better Outcomes, Lower Cost, Worker Productivity

Retrieved on: 
Tuesday, October 18, 2022
Medical Supplies, Medical Devices, Health, Practice Management, Physical Therapy, Managed Care, Work, Top, Fatigue, Prevalence, Transport, LBP, Neck, Patient, Back pain, Human, Low back pain, Twitter, Walking, Pelvis, Nursing, Spine, Foot Levelers, Disability, FIR, Shoe, CEO, Pain scale, Running, Occupation, Audio leveler, Far infrared, Poultry, Instagram, Facebook, Foot

Foot Levelers , the worlds leading provider of hand-crafted custom flexible orthotics serving multi-disciplinary professionals and clinicians, advises decision makers during open enrollment 2023 as they design benefits packages.

Key Points: 
  • Foot Levelers , the worlds leading provider of hand-crafted custom flexible orthotics serving multi-disciplinary professionals and clinicians, advises decision makers during open enrollment 2023 as they design benefits packages.
  • A key step in successfully addressing back pain is to evaluate and treat dysfunction of the feet which may be the root of many spine problems and associated pain.
  • Foot Levelers custom flexible orthotics are the only ones that support all three arches of the foot for total body alignment and stability.
  • Foot Levelers, the worlds leading provider of hand-crafted custom orthotics, has been serving healthcare professionals since 1952.

EQS-News: A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

Retrieved on: 
Monday, October 17, 2022
Disease, Therapy, Degenerative disease, Neurodegeneration, Lineage Cell Therapeutics, NYSE, NASDAQ, Patient, Back pain, MSC, Regeneration, Cell, Food and Drug Administration, Cancer, Solution, Food, Obesity, Microsoft, Lists of diseases, Pain scale, Diabetes, Advertising, Regenerative medicine, FDA, B cell, Tissue engineering, Medical device, Pharmaceutical industry

One flourishing field in biotech is regenerative medicine, a market worth $16.9 billion in 2021.

Key Points: 
  • One flourishing field in biotech is regenerative medicine, a market worth $16.9 billion in 2021.
  • There are wide applications for such regenerative therapy, with categories including stem cell research, gene therapy and tissue engineering.
  • Some difficulties for regenerative medicine companies include arduous Food and Drug Administration (FDA) trial processes and the need for vertical integration of their product development to cut expenses.
  • Here is a look at some companies looking to be leaders in the regenerative therapy field:
    Mesoblast Ltd. develops novel treatments for back pain and various cardiovascular conditions.

2022 Hepatitis D Drugs in Development Report - Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Health, Pharmaceutical, News, Therapy, Fatigue, SEC, Infection, Research, HDV, Risk factor, Company, ROA, Pain scale, History, D, R, Decision-making, Vomiting, Liver, Skin, Mall of America, Hepatitis D, Arthralgia, Vaccine, Pharmaceutical industry, Surveying, Marketing, Discovery

Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Key Points: 
  • Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.
  • The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.

Experimental Treatment Approach Counters Allergic Asthma without Weakening Flu Defenses

Retrieved on: 
Friday, October 7, 2022
Tao, National Institutes of Health, Medical research, NYU, New York University Grossman School of Medicine, Novo Nordisk Foundation, Science Advances, National, Icahn School of Medicine at Mount Sinai, Lung, German Research Foundation, Pathology, Virus, Feces, Infection, Inflammation, Breathe Me, Mouse, Center, Department, Mount Sinai School, Korea Disease Control and Prevention Agency, Wang, Asthma, Child, Cough, Society, Calcium, Cell, ORAI1, American Society of Hematology, Allergen, Membrane protein, St. Jude Children's Research Hospital, Immunoglobulin E, NYU Langone Health, Wheeze, Acute pancreatitis, Eosinophil, Gene expression, Experimental pathology, Disease, CRAC, Cytokine, Pain scale, MD, Doctor of Philosophy, Bernard Levin, COVID-19, Vaccine, Pharmaceutical industry, Science, T helper cell, New York University

Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.

Key Points: 
  • Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.
  • Allergic asthma is characterized by increased type 2 (T2) inflammation, which involves a subset of T cells called T helper (Th) 2 cells, say the study authors.
  • Without calcium entering through CRAC channels, T cells are unable to become Th2 cells and produce the cytokines that cause allergic asthma, the authors say.
  • "This suggests CRAC channel inhibition as a promising, potential future treatment approach for allergic airway disease."

Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE™ Platform at Next Generation Undruggable Conference

Retrieved on: 
Thursday, October 6, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, LinkedIn, Ventus, Therapy, NLRP3, Resolve, Inflammation, Company, Industry, Health, Neurology, Pain scale, COVID-19, Fine chemical

As an end-to-end drug discovery platform, ReSOLVE allows Ventus to advance novel differentiated small molecules in a much more time- and cost-efficient manner than conventional drug discovery approaches.

Key Points: 
  • As an end-to-end drug discovery platform, ReSOLVE allows Ventus to advance novel differentiated small molecules in a much more time- and cost-efficient manner than conventional drug discovery approaches.
  • For more information about Ventus ReSOLVE platform and drug pipeline, visit: www.VentusTx.com .
  • For more information on the Annual Next Generation Undruggable event, visit: www.nextgenerationundruggable.com .
  • For more information, please visit www.ventustx.com and engage with Ventus on Twitter @Ventus_Tx or on LinkedIn .

Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Real-World Evidence, Form 10-Q, Cholestasis, Alagille syndrome, NASDAQ, Diarrhea, Pregnancy, Primary sclerosing cholangitis, Cholestatic pruritus, Gastrointestinal bleeding, Database, Vomiting, Vitamin A, IBAT, European Medicines Agency, Congress, 2021 Essex County Council election, Primary biliary cholangitis, Biliary atresia, Annual general meeting, Liver, Bone, Medication, Skin, VISTAS, FDA, Child, FSV, Institute of Liver and Biliary Sciences, Nausea, Hospital, Breakthrough therapy, Society, Research, Degenerative disease, Form 10-K, DRS, Pain, Stomach, Pain scale, Marketing, Vitamin, SEC, Liver injury, Abdomen, GALA, Food, PFIC, Symptoms of COVID-19, Form, Hospital for Sick Children (Toronto), Health insurance, Pharmaceutical industry, Nutrition, Bachelor of Medicine, Bachelor of Surgery, Patient

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando, Florida.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando, Florida.
  • Mirum will host a scientific symposium, Beyond Itch: Exploring the Clinical Benefits of Treating Cholestasis in Children, featuring Drs.
  • The event will take place on Thursday, October 13, 2022 from 7:15-8:45pm ET in Sebastian L 1/2.
  • LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million

Retrieved on: 
Thursday, September 29, 2022
Cough, Headache, National, Federal, Infection, Department, Mycobacterium avium complex, Burkholderia pseudomallei, AN2, Chest pain, Breathe Me, Disease, Entrepreneurship, Ulcer, NIAID, U.S. Securities and Exchange Commission, Pain scale, Macrophage, Private Securities Litigation Reform Act, National Institutes of Health, Therapy, Environment, Gulf Coast of the United States, Patient, Melioidosis, Forward-looking statement, Pain, National Institute of Allergy and Infectious Diseases, Global health, MAC, Human services, Bacteria, Nasdaq, Degenerative disease, United States Department of Health and Human Services, Water, GLOBE, Fever, SEC, Mortality, Mycobacterium, NIH, NTM, Swelling, Premature ventricular contraction, National Institute, Vaccine, Pharmaceutical industry, Work, Burkholderia

AN2 Therapeutics is currently developing epetraborole in an ongoing pivotal Phase 2/3 trial for treatment refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial (NTM) lung disease.

Key Points: 
  • AN2 Therapeutics is currently developing epetraborole in an ongoing pivotal Phase 2/3 trial for treatment refractory Mycobacterium avium complex (MAC) lung disease, the most common form of nontuberculous mycobacterial (NTM) lung disease.
  • Epetraborole has shown significant promise in non-clinical models of infection for melioidosis and could have the potential to reduce mortality in patients suffering from the disease.
  • We are pleased to partner with the NIH on this meaningful global health work that is core to our corporate mission and values.
  • AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs.

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, General Health, Health, Pharmaceutical, Health Technology, Therapy, Inflammation, Health, Multiple sclerosis, Lists of diseases, Chronic kidney disease, COVID-19, NLRP3, NASH, Inflammasome, LinkedIn, Company, Senior, Rheumatism, Industry, Program, Patient, CEO, Protein, Fatty liver disease, Liver, Pyroptosis, Neurology, Research, Novo Nordisk, Kidney, Pain scale, Resolve, Fine chemical, Pharmaceutical industry, Ventus

Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.

Key Points: 
  • Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.
  • In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus lead NLRP3 inhibitor program for a broad range of diseases, including nonalcoholic steatohepatitis (NASH), chronic kidney disease, and other cardiometabolic conditions.
  • In addition, Ventus retains worldwide rights to the companys distinct brain-penetrant NLRP3 inhibitor program.
  • Ventus has developed a highly differentiated NLRP3 inhibitor program with best-in-class properties and compelling pre-clinical results.

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

Retrieved on: 
Tuesday, September 27, 2022
Adult, Cough, Half-life, Therapy, Inflammation, Pain scale, FENO, Time, ICS, HKEX, TSLP, Asthma, Antibody, OCS, Company, Patient, Type 2, History, Technology, Quality of life, HBM, H2L2, Wheeze, Multimedia, Disease, Degenerative disease, LABA, Fine chemical, Vaccine, Pharmaceutical industry

According to the strategic collaboration and agreement between HBM and Kelun-Biotech, the parties will jointly explore more innovative therapies of monoclonal antibodies and antibody-drug conjugates.

Key Points: 
  • According to the strategic collaboration and agreement between HBM and Kelun-Biotech, the parties will jointly explore more innovative therapies of monoclonal antibodies and antibody-drug conjugates.
  • HBM9378/SKB378 is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) platform.
  • Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology.
  • The Company's proprietary antibody technology platforms Harbour Micegenerate fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format.